Financial Performance - In 2024, Livzon Pharmaceutical Group achieved a revenue of RMB 11,812.34 million and a net profit attributable to shareholders of RMB 2,061.10 million[10]. - The company achieved a total revenue of RMB 12,430.04 million, with a year-on-year decrease of 4.97%[21]. - The net profit attributable to shareholders was RMB 1,953.65 million, reflecting a decline of 8.31% compared to the previous year[21]. - The company reported a net cash flow from operating activities of RMB 2,061.10 million, showing a significant increase of 51.80%[21]. - The company’s basic earnings per share for the year was RMB 2.10, with a diluted earnings per share of RMB 2.24[21]. - The company reported a total operating revenue for the year 2024 of RMB 11,812,338,854.68, representing a decrease of 4.97% compared to RMB 12,430,038,325.82 in 2023[106]. - The net profit attributable to shareholders increased by 5.50% to RMB 2,061,095.80 million in 2024[54]. - The company reported a gross margin of 45%, maintaining a stable margin compared to the previous year[37]. Research and Development - Research and development (R&D) investment accounted for 8.84% of total revenue, focusing on gastrointestinal, reproductive assistance, and mental health fields[14]. - The company has 45 products in the pipeline, including 23 innovative drugs and high-barrier complex formulations[14]. - Livzon has introduced six new projects through business development collaborations, enhancing its R&D pipeline[16]. - AI technology has been integrated into the entire R&D process, significantly improving efficiency[16]. - The company plans to increase investment in innovative drug research and development, focusing on core therapeutic areas such as digestive, mental health, and reproductive health[19]. - The company is focusing on self-research and business development (BD) to drive innovation, with a particular emphasis on gastrointestinal, reproductive, and neurological fields[73]. - The company has multiple products in various stages of clinical trials, including 3 in Phase III and 2 in Phase I[80]. - The company has established a modular and flat R&D management system to improve efficiency in project management and resource allocation[73]. Market Expansion - The company is expanding its market presence from emerging markets to Europe and the United States, optimizing its product offerings[17]. - Livzon is expanding its market presence in Southeast Asia, aiming to increase sales by 25% in that region[37]. - The company is actively pursuing international partnerships to introduce advanced technologies and expand its competitive products into global markets[93]. - The company has established branches in Malaysia and offices in Brazil, India, Spain, Vietnam, and Turkey to enhance its global commercialization strategy[101]. Product Development - Livzon plans to launch three new products in the next fiscal year, focusing on innovative drug development and biotechnology[37]. - The company has initiated Phase III clinical trials for a recombinant anti-IL-17A/F monoclonal antibody for psoriasis, aiming for market approval by 2025[76]. - The company has received approvals for three products during the reporting period, including potassium bismuth citrate granules and hydrochloride pramipexole tablets (8mg)[81]. - The company is focusing on high clinical value products, with a complete matrix of assisted reproductive products expected to enhance market presence[79]. - The company is advancing its research in traditional Chinese medicine, targeting mental health and chronic diseases, with two products expected to report this year[79]. Compliance and Sustainability - The company maintains a 100% compliance rate with GMP inspections for all production lines of listed products[18]. - The company has received MSCI ESG AAA rating for two consecutive years and was recognized as the "Best Progress Company" in the 2024 S&P Global Sustainability Yearbook[19]. - The company integrates sustainable development goals into management performance assessments, promoting green production and social responsibility[94]. - The company has established a standardized public welfare management system focusing on rural revitalization, education support, medical assistance, and disaster response, contributing to local farmers' income through the "Huangqi Industry Revitalization" project[95]. Financial Management - The company reported a total investment amount of RMB 1,711,305,473.04, representing a 134.54% increase compared to RMB 729,635,150.00 in the previous year[161]. - The company has established risk management measures for foreign exchange and commodity futures derivatives to mitigate market risks associated with currency and commodity price fluctuations[171]. - The company has not engaged in speculative derivative investments during the reporting period[172]. - The company has implemented strict internal controls to reduce operational risks related to derivative trading[171]. Customer and Supplier Relations - The average duration of the top five customers' relationship with the company is 16.60 years, indicating strong customer loyalty[114]. - The company’s total revenue from the top five customers was RMB 947,987,674.38, representing 8.10% of the total annual sales, slightly down from 8.19% in 2023[115]. - The total procurement amount from the top five suppliers was RMB 706,067,451.82, which accounted for 32.15% of the total procurement, an increase from 26.06% in 2023[119].
丽珠医药(01513) - 2024 - 年度财报